Results 91 to 100 of about 111,943 (300)

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

Guideline for screening and diagnosing gestational diabetes mellitus [PDF]

, 2015
Gestational diabetes mellitus (GDM) is on the rise, especially with the increase in obesity in childbearing women as well as the rising prevalence of diabetes mellitus type 2.
Craus, Johann, Savona-Ventura, Charles, Cuschieri, Sarah   +2 more
core  

Screening for cystic fibrosis-related diabetes : a systematic review [PDF]

, 2012
Background Cystic fibrosis (CF) is an inherited disease that leads to damage to lungs, pancreas and other organs. Most people with CF die prematurely from lung disease, but survival has improved markedly over the decades and it is estimated that ...
P Royle, N Waugh, A Adler, Ewings, P., C Sheldon, L Pandit, Adler, A. (Amanda), Craigie, I., I Craigie, Sheldon, C. (Christopher), P Ewings, Waugh, Norman, V Ho, P Helms, Helms, Peter, Prof., Royle, Pamela, Pandit, L., Ho, V.   +17 more
core   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Loss of AMP-activated protein kinase alpha 2 subunit in mouse beta-cells impairs glucose-stimulated insulin secretion and inhibits their sensitivity to hypoglycaemia [PDF]

, 2010
AMPK (AMP-activated protein kinase) signalling plays a key role in whole-body energy homoeostasis, although its precise role in pancreatic beta-cell function remains unclear.
Withers, DJ, Ashford, ML, Smith, Mark A., Al-Qassab, H, Piipari, K, Piipari, Kaisa, Al-Qassab, Hind, Smith, Mark A, Viollet, Benoit, Ashford, Michael Lj, Viollet, B, Beall, Craig, Smith, MA, Withers, Dominic J, Parker, N, Carling, David, Parker, Nadeene, Withers, Dominic J., Ashford, Michael L. J.; id_orcid, Beall, C, Carling, D   +20 more
core   +1 more source

A guide to neuromodulation in drug‐resistant epilepsy

Epileptic Disorders, EarlyView.
Abstract Neuromodulation is approved for the treatment of drug‐resistant epilepsy. It has been increasingly utilized over the past two decades with the approval of deep brain stimulation (DBS) and responsive neurostimulation (RNS) in addition to vagus nerve stimulation (VNS)—particularly in patients who are not deemed to be good resective surgical ...
Prachi Parikh, Irena Dolezawa, Manu Hegde, Lukas Imbach, Brian N. Lundstrom, Francesca Pizzo, Vikram R. Rao, Jaysingh Singh, Derek Southwell, Satsuke Watanabe, Birgit Frauscher   +10 more
wiley   +1 more source

Glucose effectiveness is a critical pathogenic factor leading to glucose intolerance and type 2 diabetes: An ignored hypothesis [PDF]

, 2018
Background: Although the ability of glucose to mediate its own in vivo metabolism is long documented, the quantitative measurement of whole body glucose-mediated glucose disposal at basal insulin levels (glucose effectiveness [GE]), followed the ...
Rantzau, C., H. Beck-Nielsen, J.E. Henriksen, Alford, F. P., Beck-Nielsen, H., C. Rantzau, F.P. Alford, Henriksen, J. E.   +7 more
core   +1 more source

Clinical utility and genetic landscape of exome sequencing in a large pediatric epilepsy cohort: Insights from a Turkish tertiary care center

Epileptic Disorders, EarlyView.
Abstract Objective To evaluate the diagnostic utility and genetic spectrum of next‐generation sequencing (NGS) in a large, well‐phenotyped cohort of Turkish pediatric patients with epilepsy of unknown etiology. Methods Between January 2021 and December 2024, 250 children (115 female, 135 male) with unexplained epilepsy underwent either whole‐exome ...
Derya Karaer, Beste Kipçak Yüzbaşı, İpek Şahin, Olcay Güngör, Kadri Karaer   +4 more
wiley   +1 more source

Clinical implications of combined glucose intolerance in treatment-naïve hypertensive patients

Clinical and Experimental Hypertension, 2018
Background: This study is the first study to evaluate clinical significance of combined glucose intolerance (CGI) in treatment-naïve hypertensive patients. Methods: We compared the results of demographic, anthropometric, clinical, laboratory examinations,
Beom-June Kwon, Dae-Won Kim, Mahn-Won Park, Sung-Ho Her, Ha Wook Park, Kiyuk Chang, Wook-Sung Chung, Ki-Bae Seung, Tai-Ho Rho   +8 more
doaj   +1 more source

Inherited metabolic epilepsies–established diseases, new approaches

Epilepsia Open, EarlyView.
Abstract Inherited metabolic epilepsies (IMEs) represent the inherited metabolic disorders (IMDs) in which epilepsy is a prevailing component, often determining other neurodevelopmental outcomes associated with the disorder. The different metabolic pathways affected by individual IMEs are the basis of their rarity and heterogeneity.
Itay Tokatly Latzer, Phillip L. Pearl
wiley   +1 more source